Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 5;13:868830. doi: 10.3389/fphar.2022.868830

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yuan, Zhang, Deng, Xia, Li, Meng, Jin, Cheng, Li, Zhang and He.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Identification of epigenetic modification-related LncRNA (EMRL). (A) Doughnut charts showed the distribution of DHMS or MMS in each modification type. (B)Venn diagram showed the overlaps of EMRG (or EMRL) regulated by different modification types. PCG refers to the protein-coding genes, and LncRNA refers to the long non-coding RNAs. (C) MNX1-AS1 was potentially regulated by H3K4me3 and H3K27ac in GC cell lines. Peaks in yellow and green refer to H3K4me3 and H3K27ac, respectively, while gray ones refer to the corresponding modification in GES-1 as control. The red line at the bottom refers to the promoter region. (D) m6A modification regions of MNX1-AS1 in the AGS cell line. Peaks in blue refer to the immunoprecipitation (IP) signals. Peaks in gray refer to the input signals. (E) Differential expression of MNX1-AS1 in GC cell lines and GES-1 (p < 0.05). (F) Correlations of MNX1-AS1 with the m6A regulators including HNRNPC, HNRNPA2B1, and IGF2BP2 (Spearman, p < 0.05).